N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH$_2$CH$_3$, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

32 (New). A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration, and diabetic retinopathy comprising N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH$_2$CH$_3$, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

REMARKS

Claims 1-17 were pending in the subject application. After entry of this amendment, claims 1-14, 16, and 18-32 will be pending.

The amendment accompanying these remarks cancels claims 15 and 17 as being outside the scope of elected Group 1 and amends claim 1 to recite the amino acyl residue "glycyl" as option (13) under A_2, to remove variables in claim 1 which are outside the scope of Group 1, and to correct a minor typographical error.

Support for the recitation of glycyl in claim 1 is found on page 19, lines 15-19 and in Examples 1-152, 161-334, 337 (in part), 339 (in part), and 340-356 in the specification.

CONCLUSION

This amendment addresses the issues raised in the Official action and places the claims in condition for allowance. Entry of the proposed amendment and allowance of Claims 1-14, 16, and 18-32 is respectfully requested.

Respectfully submitted,
J. Henkin, et al.

23492
23492

ABBOTT LABORATORIES
Telephone: (847) 937-3810
Facsimile: (847) 938-2623

B. Gregory Donner
Registration No. 34,580
Attorney for Applicants

VERSION OF CLAIMS WITH MARKINGS TO SHOW CHANGES MADE

1 (Amended). A compound of the formula:

$$A_0\text{-}A_1\text{-}A_2\text{-}A_3\text{-}A_4\text{-}A_5\text{-}A_6\text{-}A_7\text{-}A_8\text{-}A_9\text{-}A_{10}$$

or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, wherein:

A_0 is **[hydrogen or]** an acyl group selected from:

(1) $R\text{-}(CH_2)_n\text{-}C(O)\text{-}$; wherein n is an integer from 0 to 8 and R is selected from hydroxyl; methyl; N-acetylamino; methoxyl; carboxyl; cyclohexyl optionally containing a one or two double bonds and optionally substituted with one to three hydroxyl groups; and a 5- or 6-membered ring aromatic or nonaromatic ring optionally containing one or two heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the ring is optionally substituted with a moiety selected from alkyl, alkoxy, and halogen; and

(2) $R^1\text{-}CH_2CH_2\text{-}(OCH_2CH_2O)_p\text{-}CH_2\text{-}C(O)\text{-}$; wherein R^1 is selected from hydrogen, alkyl, and N-acetylamino, and p is an integer from 1 to 8;

A_1 is an amino acyl residue selected from:

(1) alanyl,
(2) asparaginyl,
(3) citrullyl,
(4) glutaminyl,
(5) glutamyl,
(6) N-ethylglycyl,
(7) methionyl,
(8) N-methylalanyl,
(9) prolyl,
(10) pyro-glutamyl,
(11) sarcosyl,
(12) seryl,

(13) threonyl,

(14) -HN-$(CH_2)_q$-C(O)-, wherein q is 1 to 8, and

(15) -HN-CH_2CH_2-$(OCH_2CH_2O)_r$-CH_2-C(O)-, wherein r is 1 to 8;

A_2 is an amino acyl residue selected from:

(1) alanyl,

(2) asparaginyl,

(3) aspartyl,

(4) glutaminyl,

(5) glutamyl,

(6) leucyl,

(7) methionyl,

(8) phenylalanyl,

(9) prolyl,

(10) seryl,

(11) -HN-$(CH_2)_q$-C(O)-, wherein q is 1 to 8, **[and]**

(12) -HN-CH_2CH_2-$(OCH_2CH_2O)_r$-CH_2-C(O)-, wherein r is 1 to 8**[;]**, **and**

(13) glycyl;

A_3 is an amino acyl residue selected from:

(1) alanyl,

(2) asparaginyl,

(3) citrullyl,

(4) cyclohexylalanyl,

(5) cyclohexylglycyl,

(6) glutaminyl,

(7) glutamyl,

(8) glycyl,

(9) isoleucyl,

(10) leucyl,

(11) methionyl,

(12) norvalyl,

(13) phenylalanyl,

(14) seryl,

(15) *t*-butylglycyl,

(16) threonyl,

(17) valyl,

(18) penicillaminyl, and

(19) cystyl;

A_4 is an amino acyl residue of L or D configuration selected from:

(1) allo-isoleucyl,

(2) glycyl,

(3) isoleucyl,

(4) prolyl,

(5) dehydroleucyl,

(6) D-alanyl,

(7) D-3-(naphth-1-yl)alanyl,

(8) D-3-(naphth-2-yl)alanyl,

(9) D-(3-pyridyl)-alanyl,

(10) D-2-aminobutyryl,

(11) D-allo-isoleucyl,

(12) D-allo-threonyl,

(13) D-allylglycyl,

(14) D-asparaginyl,

(15) D-aspartyl,

(16) D-benzothienyl,

(17) D-3-(4,4'-biphenyl)alanyl,

(18) D-chlorophenylalanyl,

(19) D-3-(3-trifluoromethylphenyl)alanyl,

(20) D-3-(3-cyanophenyl)alanyl,

(21) D-3-(3,4-difluorophenyl)alanyl,

(22) D-citrullyl,

(23) D-cyclohexylalanyl,

(24) D-cyclohexylglycyl,

(25) D-cystyl,

(26) D-cystyl(*S*-*t*-butyl),

(27) D-glutaminyl,

(28) D-glutamyl,

(29) D-histidyl,

(30) D-homoisoleucyl,

(31) D-homophenylalanyl,
(32) D-homoseryl,
(33) D-isoleucyl,
(34) D-leucyl,
(35) D-lysyl(N-epsilon-nicotinyl),
(36) D-lysyl,
(37) D-methionyl,
(38) D-neopentylglycyl,
(39) D-norleucyl,
(40) D-norvalyl,
(41) D-ornithyl,
(42) D-penicillaminyl,
(43) D-penicillaminyl(acetamidomethyl),
(44) D-penicillaminyl(*S*-benzyl),
(45) D-phenylalanyl,
(46) D-3-(4-aminophenyl)alanyl,
(47) D-3-(4-methylphenyl)alanyl,
(48) D-3-(4-nitrophenyl)alanyl,
(49) D-3-(3,4-dimethoxyphenyl)alanyl,
(50) D-3-(3,4,5-trifluorophenyl)alanyl,
(51) D-prolyl,
(52) D-seryl,
(53) D-seryl(*O*-benzyl),
(54) D-*t*-butylglycyl,
(55) D-thienylalanyl,
(56) D-threonyl,
(57) D-threonyl(*O*-benzyl),
(58) D-tryptyl,
(59) D-tyrosyl(*O*-benzyl),
(60) D-tyrosyl(*O*-ethyl),
(61) D-tyrosyl, and
(62) D-valyl;

A_5 is an amino acyl residue of L or D configuration selected from:

(1) alanyl,

(2) (3-pyridyl)alanyl,
(3) 3-(naphth-1-yl)alanyl,
(4) 3-(naphth-2-yl)alanyl,
(5) allo-threonyl,
(6) allylglycyl,
(7) glutaminyl,
(8) glycyl,
(9) histidyl,
(10) homoseryl,
(11) isoleucyl,
(12) lysyl(N-epsilon-acetyl),
(13) methionyl,
(14) norvalyl,
(15) octylglycyl,
(16) ornithyl,
(17) 3-(4-hydroxymethylphenyl)alanyl,
(18) prolyl,
(19) seryl,
(20) threonyl,
(21) tryptyl,
(22) tyrosyl,
(23) D-allo-threonyl,
(24) D-homoseryl,
(25) D-seryl,
(26) D-threonyl,
(27) penicillaminyl, and
(28) cystyl;

A_6 is an amino acyl residue of L or D configuration selected from:

(1) alanyl,
(2) 3-(naphth-1-yl)alanyl,
(3) 3-(naphth-2-yl)alanyl,
(4) (3-pyridyl)alanyl,
(5) 2-aminobutyryl,
(6) allylglycyl,

(7) arginyl,
(8) asparaginyl,
(9) aspartyl,
(10) citrullyl,
(11) cyclohexylalanyl,
(12) glutaminyl,
(13) glutamyl,
(14) glycyl,
(15) histidyl,
(16) homoalanyl,
(17) homoleucyl,
(18) homoseryl,
(19) isoleucyl,
(20) leucyl,
(21) lysyl(N-epsilon-acetyl),
(22) lysyl(N-epsilon-isopropyl),
(23) methionyl(sulfone),
(24) methionyl(sulfoxide),
(25) methionyl,
(26) norleucyl,
(27) norvalyl,
(28) octylglycyl,
(29) phenylalanyl,
(30) 3-(4-carboxyamidephenyl)alanyl,
(31) propargylglycyl,
(32) seryl,
(33) threonyl,
(34) tryptyl,
(35) tyrosyl,
(36) valyl,
(37) D-3-(naphth-1-yl)alanyl,
(38) D-3-(naphth-2-yl)alanyl,
(39) D-glutaminyl,
(40) D-homoseryl,

(41) D-leucyl,
(42) D-norvalyl,
(43) D-seryl,
(44) penicillaminyl, and
(45) cystyl;

A_7 is an amino acyl residue of L or D configuration selected from:

(1) alanyl,
(2) allylglycyl,
(3) aspartyl,
(4) citrullyl,
(5) cyclohexylglycyl,
(6) glutamyl,
(7) glycyl,
(8) homoseryl,
(9) isoleucyl,
(10) allo-isoleucyl
(11) leucyl,
(12) lysyl(N-epsilon-acetyl),
(13) methionyl,
(14) 3-(naphth-1-yl)alanyl,
(15) 3-(naphth-2-yl)alanyl,
(16) norvalyl,
(17) phenylalanyl,
(18) prolyl,
(19) seryl,
(20) *t*-butylglycyl,
(21) tryptyl,
(22) tyrosyl,
(23) valyl,
(24) D-allo-isoleucyl,
(25) D-isoleucyl,
(26) penicillaminyl, and
(27) cystyl;

A_8 is an amino acyl residue selected from:

(1) 2-amino-4-[(2-amino)-pyrimidinyl]butanoyl,
(2) alanyl(3-guanidino),
(3) alanyl[3-pyrrolidinyl(2-N-amidino)],
(4) alanyl[4-piperidinyl(N-amidino)],
(5) arginyl,
(6) arginyl($N^{G}N^{G'}$diethyl),
(7) citrullyl,
(8) 3-(cyclohexyl)alanyl(4-N'-isopropyl),
(9) glycyl[4-piperidinyl(N-amidino)],
(10) histidyl,
(11) homoarginyl,
(12) lysyl,
(13) lysyl(N-epsilon-isopropyl),
(14) lysyl(N-epsilon-nicotinyl),
(15) norarginyl,
(16) ornithyl(N-delta-isopropyl),
(17) ornithyl(N-delta-nicotinyl),
(18) ornithyl[N-delta-(2-imidazolinyl)],
(19) [(4-amino(N-isopropyl)methyl)phenyl]alanyl,
(20) 3-(4-guanidinophenyl)alanyl, and
(21) 3-(4-amino-N-isopropylphenyl)alanyl;

A_9 is an amino acyl residue of L or D configuration selected from:

(1) 2-amino-butyryl,
(2) 2-amino-isobutyryl,
(3) homoprolyl,
(4) hydroxyprolyl,
(5) isoleucyl,
(6) leucyl,
(7) phenylalanyl,
(8) prolyl,
(9) seryl,
(10) *t*-butylglycyl,
(11) 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
(12) threonyl,

(13) valyl,

(14) D-alanyl, and

(15) D-prolyl; and

A_{10} is a hydroxyl group or an amino acid amide is selected from:

azaglycylamide,

D-alanylamide,

D-alanylethylamide,

glycylamide,

glycylethylamide,

sarcosylamide,

serylamide,

D-serylamide,

a group represented by the formula

, and

a group represented by the formula -NH-R^4;

wherein:

s is an integer selected from 0 to 8,

R^2 is selected from hydrogen, alkyl, and a 5- to 6-membered cycloalkyl ring;

R^3 is selected from hydrogen, hydroxy, alkyl, phenyl, alkoxy, and a 5- to 6-membered ring optionally containing from one to two heteroatoms selected from oxygen, nitrogen, and sulfur, provided that s is not zero when R^3 is hydroxy or alkoxy; and

R^4 is selected from hydrogen, hydroxy, and a 5- to 6-membered cycloalkyl ring.